November 24, 2014

ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.

"We believe the new data being reported with our IMGN529 and IMGN779 ADCs will help convey why we believe these have the potential to make important differences for patients with certain B-cell malignancies and acute myeloid leukemia, respectively," commented Daniel Junius, President and CEO. "We expect to advance IMGN529 into disease-specific testing in the first half of 2015 and IMGN779 into initial clinical testing in the second half of 2015. Our partners continue to make progress as well, with new clinical data to be presented with Biotest's indatuximab ravtansine, or BT-062, ADC and Sanofi's SAR650984 CD38-targeting antibody."

Presentations on ImmunoGen Wholly Owned ADCs

Title: "A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)."

- Poster session (PS) #624: Saturday, Dec. 6, 5:30-7:30 pm PST. Abstract #1760.

Title: "Preclinical Mechanistic Studies Investigating Neutrophil and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting Antibody-Drug Conjugate (ADC)."

- PS #625: Sunday, Dec. 7, 6:00-8:00 pm PST. Abstract #3119.

Title: "The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations."

- PS #616: Sunday, Dec. 7, 6:00-8:00 pm PST. Abstract #2321.

Presentations on Partner Compounds

Title: "SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide."

- PS #653: Saturday, Dec. 6, 5:30-7:30 pm PST. Abstract #2124.

Title: "KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone."

- PS #653: Saturday, Dec. 6, 5:30-7:30 pm PST. Abstract #2126.

Title: "A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma."

- Presentation time: Sunday, Dec. 7, at 1:00 pm PST. Abstract #83.

Title: "Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib."

- PS #653: Monday, Dec. 8, 6:00-8:00 pm PST. Abstract #4736.

Additional information can be found at www.hematology.org, including the abstracts.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds in clinical testing through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, IMGN779, BT-062, and SAR650984, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2014 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085

Source: ImmunoGen, Inc.